SG10201803321TA - Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate - Google Patents

Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Info

Publication number
SG10201803321TA
SG10201803321TA SG10201803321TA SG10201803321TA SG10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA
Authority
SG
Singapore
Prior art keywords
dimethylamino
propionate
dodecyl
ddaip
active enantiomer
Prior art date
Application number
SG10201803321TA
Inventor
Bassam B Damaj
Richard Martin
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of SG10201803321TA publication Critical patent/SG10201803321TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE 2R-dodecyl 2-(N,N dimethylamino)-propionate (R-DDAIP) provides an unexpectedly improved activity in facilitating transport of a pharmaceutically active compound across biological membranes and tissues, compared to SDDAIP of the same enantiomeric purity, or racemic DDAIP. Purified S-DDAIP is also provided. FIG. 1
SG10201803321TA 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate SG10201803321TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41899610P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
SG10201803321TA true SG10201803321TA (en) 2018-06-28

Family

ID=46172526

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803321TA SG10201803321TA (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
SG2013035258A SG190199A1 (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013035258A SG190199A1 (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Country Status (19)

Country Link
US (1) US20130267562A1 (en)
EP (1) EP2646015B1 (en)
JP (1) JP6109075B2 (en)
KR (1) KR102004552B1 (en)
CN (1) CN103930105B (en)
AU (2) AU2011336692B2 (en)
BR (1) BR112013012799A8 (en)
CA (1) CA2817417C (en)
CL (1) CL2013001391A1 (en)
CR (1) CR20130324A (en)
ES (1) ES2801999T3 (en)
IL (1) IL226173A (en)
MX (1) MX2013005522A (en)
NZ (1) NZ609826A (en)
PL (1) PL2646015T3 (en)
RU (1) RU2679308C2 (en)
SG (2) SG10201803321TA (en)
WO (1) WO2012075107A2 (en)
ZA (1) ZA201304840B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028780A2 (en) * 2012-08-15 2014-02-20 Nexmed Holdings, Inc. Antifungal compounds and methods of use
US8900625B2 (en) 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
DE10033853A1 (en) * 2000-07-12 2002-01-31 Hexal Ag Transdermal therapeutic system, containing highly dispersed silicon dioxide in matrix or adhesive layer to promote drug permeation through the skin
BRPI0312007B1 (en) * 2002-06-25 2015-04-14 Acrux Dds Pty Ltd Pharmaceutical composition for transcutaneous administration of testosterone or fentanyl and use of said composition
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
NZ542904A (en) * 2003-03-21 2009-04-30 Nexmed Holdings Inc Antifungal nail coat and method of use
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
JP5619337B2 (en) * 2003-10-10 2014-11-05 フェリング ビー.ブイ. Transdermal pharmaceutical formulation to minimize skin residue
WO2005051960A2 (en) * 2003-11-22 2005-06-09 Midwest Research Laboratories, Llc Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
AU2011249043B2 (en) * 2010-05-04 2015-07-09 Nexmed Holdings, Inc. Compositions of small molecule therapeutics
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
EP2646015B1 (en) 2020-04-22
MX2013005522A (en) 2013-07-17
WO2012075107A3 (en) 2014-03-06
CN103930105A (en) 2014-07-16
CA2817417C (en) 2020-12-29
JP2014514243A (en) 2014-06-19
AU2017200314A1 (en) 2017-02-02
BR112013012799A8 (en) 2018-01-09
RU2679308C2 (en) 2019-02-07
CA2817417A1 (en) 2012-06-07
IL226173A (en) 2016-10-31
US20130267562A1 (en) 2013-10-10
ES2801999T3 (en) 2021-01-15
CR20130324A (en) 2013-08-13
KR102004552B1 (en) 2019-10-01
EP2646015A4 (en) 2015-04-08
IL226173A0 (en) 2013-07-31
CL2013001391A1 (en) 2013-11-08
SG190199A1 (en) 2013-06-28
AU2011336692B2 (en) 2017-02-16
KR20140023875A (en) 2014-02-27
CN103930105B (en) 2019-11-01
BR112013012799A2 (en) 2016-09-13
AU2011336692A1 (en) 2013-05-30
JP6109075B2 (en) 2017-04-05
NZ609826A (en) 2016-03-31
ZA201304840B (en) 2014-04-30
WO2012075107A2 (en) 2012-06-07
EP2646015A2 (en) 2013-10-09
RU2013119439A (en) 2015-01-10
PL2646015T3 (en) 2020-11-30

Similar Documents

Publication Publication Date Title
USD831829S1 (en) Dental implant reusable bite registration post
USD659247S1 (en) Dental implant
WO2007139933A3 (en) Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
ZA201004694B (en) Use of a fertilizer containing l-amino acid for improving root growth and growth of mycorrhiza
GEP20146100B (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
RS53521B1 (en) Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
USD811211S1 (en) Catheter package
MX2009006288A (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-b enzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
USD653879S1 (en) Table
MX2012007590A (en) Composition for improving brain function and method for improving brain function.
MX2009012472A (en) Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis.
AR078283A1 (en) ORAL SUSPENSION FORMULATIONS OF DIBENZAZEPINA CARBOXAMIDAS
USD673458S1 (en) Package face
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
SG10201803321TA (en) Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
HRP20060079B1 (en) Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
IL209583A0 (en) 1 - (2-ethyl-butyl) - cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides
USD645504S1 (en) Writing paper
USD617054S1 (en) Rugby jumper support grip
RS53896B1 (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
WO2008155920A1 (en) Drug having effect of promoting hepatocyte growth
USD723932S1 (en) Bottle
RU2008115908A (en) PHARMACEUTICAL COMPOSITION CONTAINING HYALURONIDASE AND LIPOSOMES FOR EXTERNAL USE
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride